Highly Potent Statin Stands Out for Diabetes and Cataract Risks
Two high-intensity statin regimens showed similar clinical effectiveness when directly compared in secondary prevention, but one of them was associated with a higher risk of diabetes and cataract in the results of the LODESTAR trial. Whether randomized to rosuvastatin (Crestor) or atorvastatin (Lipitor), people with coronary heart disease (CAD) did not have a statistically significant …
